To assess the diagnostic significance of CA19-9, the serum levels in 225 healthy subjects, 201 patients with cancers, 423 patients with benign diseases and 21 pregnant women, weredetermined by RIA. The mean CA19-9 level of the healthy subjects was ll.2 ± 0.4 U/ml (range, 6-100 U/ml). Only 3.1% of them were above 37 U/ml. The CA19-9 levels were elevated above 37 U/ml in 7.9% of 293 patients with non-carcinomatous diseases of the digestive system. Amongdigestive system cancers, elevated levels were found in 18.2% of ll patients with esophageal cancer, 42.7% of 68 patients with gastric cancer, 39.1% of 23 patients with colorectal cancer, 27.8% of 18 patients with primary hepatic cancer, 71.4% of 35 patients with biliary cancer, and 75% of 20 patients with pancreatic cancer. Most of the patients with levels above 100 U/ml had carcinomatous diseases. The CA19-9 positive rates for patients with gastric cancer and colorectal cancer were extremely low at stages I, II and III, while in patients at stage IV and in patients with recurrent cancer, a tendency for rapid increase in the positive rates and concentrations of CA19-9 was noted. Based on combination assay of CA19-9, CEAand ferritin, in comparison with the positive rates for CA19-9 alone, it was found that the rates were raised to 42.7% in gastric cancer, to 39.1% in colorectal cancer, and to 71.4% in biliary cancer, suggesting the simultaneous determination with these tumor markers mayserve to elevate their usefulness.
Manyfetal antigens or antigens associated with tumor tissues, hormones, or enzymes, have been reported as tumor markers. All of them, however, lack satisfactory organ-or disease-specificity, since they have indicated high pseudo-positive rates in benign diseases, limiting their diagnostic value.
Accordingly, in the immunological and biochemical diagnosis of carcinomas, no definitive method comparable to the pathohistological diagnostic method has yet been established. The development of a serum tumor marker, excellent both in its sensitivity and specificity and usable for the early diagnosis of carcinoma, or as a parameter of the progress of carcinoma, is thus one of the most important topics in present clinical medicine.
Carbohydrate antigen CA19-9 is a large monosialoganglioside recognized by monoclonal antibody produced from hybridoma in mouse splenic cells immunized with the strain SW1116 originating from the humancolorectal carcinoma cultured by Koprowski et for CA19-9, and has applied it in clinical practice.
The diagnostic significance of this antigen has attracted our attention as a possible new tumor marker associated with carcinoma of the digestive organs.4"6' In the present study, we determined or malignant diseases, in pregnant woman,and in healthy subjects, by radioimmunoassay, and attempted to assess its diagnostic usefulness for carcinoma of the digestive organs.
METHODSAND SUBJECTS

Subjects
The subjects were inpatients or outpatients of the Third Department of Internal Medicine or the 2. Methods of determination of serum CA19-9 and other tumor markers Serum CA19-9 was determined in duplicate by a solid-state radioimmunoassay method based on the forward sandwich method, using the CA19-9
á"RIA Kit manufactured by Centcor Inc. The standard solution at each concentration, the test sera, and the control sera, were reacted with the CA19-9 monoclonal antibody coated over polystyrene beads in a thermostat trough at 37 C, and the unreacted sera were then rinsed and removed. Next, 125I-labelled CA19-9 antibody was added and incubated with the CA19-9 antigen bonded with the solid-state beads at room temperature for 3 hours (solidified antibody-antigen-125I-labelled antibody). The labelled antibody in excess was rinsed 3 times and removed. The quantity of labelled antibody bonded together with the beads was calculated using a gammacounter, and the CA19-9 concentrations in the control sera and test sera were determined by comparison with the standard curve.
The samples (sera) were stored in a freezer at -40C for the period from separation of the serum to the determination in each experiment.
In the present study, the cut-off value of serum CA19-9was set at 37 U/mlbasedonthereport of ng/ml and of elastase I 100-400 ng/ml.
RESULTS
1) Serum CA19-9 values in healthy subjects (Fig. i) The mean concentration of serum CA19-9 in 225 healthy subjects showing no abnormality not only by physical inspections, but also by ordinary clinical examinations, was ll.2 ± 10.4 U/ml (mean ± SD). The meanconcentration in the 127 male subjects was 8.5 ± 4.3 U/ml, and that in the 98 female subjects, 14.4 ± 14.2 U/ml. The latter indicated a slightly higher tendency, but no statistical significance was noted. Classification of the serum CA19-9 concentration in the healthy subjects was made by age group. The serum CA19-9 concentration in the young female group below 20 years thus revealed a higher tendency. Seven cases (3.1%) in which the serum CA19-9 value was abnormally high (over 37 U/ml) were all young females, with 6 subjects below 20 years, and 1 subject in her twenties, the highest value being 100 U/ml. The association between serum CA19-9 value and smoking and drinking habits was examined, but no significant correlation was noted. 3) Serum CA19-9values in patients with cancers (Table 1 and It was clarified therefore that the positive rate tended to be lower in cases at an early stage, whereas it was higher in cases at Stage IV or in recurrent carcinoma.
5) Relationship between histological classification
of cancer of the digestive system and the serum CA19-9 value (Fig. 6 observed between CA19-9 and ferritin (p < 0.05) in gastric cancer, and also between CA19-9 and ferritin (p < 0.01), and between CA19-9 and alpha-fetoprotein in primary liver cancer. The postive rates in which one or more of the 3 tumor markers, CA19-9, CEA and ferritin, in the sera of patients with cancer of the digestive can increase the accuracy of diagnosis.
A tumor marker has been understood as "a substance produced by the cancer cell, having a qualitative or a quantitative difference from a non-cancer cell." It is therefore considered not to be produced qualitatively under ordinary circumstances, or to be produced in only a trace amount, whereas it is produced abnormally in the cancer cell.
In recent years, investigations of the whole structure of glycochains have become one of the most important topics in the study of tumor markers. In particular, when a monoclonal antibody is made out of hybridoma, it can recognize the difference in stereoscopic position of an amino acid, and the difference in the glycochain, and reported that the mean value was 8.4 ± 7.4 U/ml (range, 0-107 U/ml), and that only 6 cases (0.6%) presented pseudopositiveness of over 37 U/ml. They stated that the mean value ofCA19-9 in male subjects did not show any significant changes with advancing age, while that in female subjects was highest in their twenties, decreasing with advancing age.
The results of the present study indicated that the mean value of serum CA19-9 in 225 healthy subjects was ll.2 ± 10.4 U/ml, and its pseudopositive rate was 3.1%. These figures were slightly higher than the mean value and pseudopositive rate for CA19-9 obtained by Del Villano et al. in healthy subjects. It was further found that the mean value of GA19-9 in female subjects was higher than that in male subjects, in their all age groups, excluding those in their forties. This tendency was particularly noticeable in younger women.
From the data obtained by several researchers3'12' as well as by the authors, the serum CA19-9 value in healthy subjects appears to be higher in young women, so that the majority of pseudopositive cases may possibly be occupied by such young women.It is considered therefore that the mean value and the pseudopositive rate of CA19-9 may vary to some extent in accordance with the age constitution and sex ratio of healthy subjects to be studied, especially the number of young womenin the population.
Unlike CEA, the serum CA19-9 in healthy subjects does not show a significant relation with smoking and drinking habits, and why the CA19-9 in young womenis higher than that in other age groups is not yet certain.
In order to differentiate patients with carcinoma and healthy subjects, or patients with benign diseases, based on determinations of the serum CA19-9, Del Villano et al.3) decided to set the cut-off value at 37 U/ml. As has been clarified in the present study, the diseases which can elevate the serum CA19-9 are multifarious, and even within the same disease, CA19-9 is widely distributed from a low to a high value. Accordingly, if we set the cut-off value of CA19-9 at a low level, many non-cancerous diseases will be included, and pseudopositive cases will be increased reducing the rate of accurate diagnosis. On the other hand, if we set the cut-off value at a high level, the rate of diagnosis of carcinomatous diseases is elevated, but the possibility of judging cancerous diseases as pseudopositive or of overlooking them completely is elevated. Taking the mean ± 2 SD of the CA19-9 value in healthy subjects determined by the authors as a standard, its upper limit becomes 32 U/ml, but some reports12' have set the cut-off value at 40 or 44 U/ml. It is important to decide an appropriate cut-off value for CA19-9as a tumor marker to have high sensitivity and specificity. At the present, the cutoff value of 37 U/ml decided by Del Villano et al. may represent an appropriate standard, since it can limit the pseudopositive rates in healthy subjects at middle or higher ages or patients with benign diseases to a rather low level. However, it is considered necessary to re-examine the cutoff value of CA19-9 based on an analysis of various background factors.
Although the serum CA19-9 in pregnant women,in patients with chronic hepatitis, hepatic cirrhosis, primary biliary cirrhosis, cholelithiasis, pancreatitis, renal insufficiency, diabetes mellitus and other benign diseases, showed positive rates of 3.6-25%, it was within the normal range in many other patients with benign digestive diseases. Amongthe 39 cases of benign diseases and pregnant womenwho were CA19-9 positive, those in whom higher values of over 100 U/ml were indicated amounted to only 3 patients including one each with hepatic cirrhosis, cholelithiasis and diabetes mellitus. In the majority of them, a mild elevation below 100 U/ml was observed. The positive rate of serum CA19-9 in the pregnant womenwas as low as 4.8%, and the meanvalue was not so high compared with that of healthy young women. This suggests that CA19-9 may have no close relationship with the fetal character. When CA19-9 was analyzed by Sephadex G-200 column-chromatography, it was eluted in the void volume, and was therefore presumed to be a high molecular substance. Further, in view of the fact that the positive rate of CA19-9 is somewhat higher in hepatic cirrhosis than in chronic hepatitis, the former being at a more advanced state of disease, and that the positive rate in patients with renal insufficiency is low, the possibility of high molecular CA19-9 being metabolized mainly in the liver can be postulated. It has been confirmed that in the bile ingredients of patients with carcinoma and with benign diseases, CA19-9 is present at a very high concentration.ll' 13' Accordingly, the elevation of srum CA19-9at attacks of choleliathiasis may be associated with impairment of bile excretion.
In the 4 cases of choleliathiasis treated by the authors in which the CA19-9 was abnormal, the determinations were made in all cases when colic and jaundice appeared, and the GA19-9 value returned immediately to the normal range when the pathological state was improved. In some patients with primary biliary cirrhosis, CA19-9 was elevated, and all the patients involved had jaundice and pruritus. Since this disease consisted of chronic non-suppurative destructive cholangitis at the interlobular bile duct of medium size (40-80 JJi in diameter) or at the septal bile duct, and its basic lesions presented a pathological state of chronic intrahepatic cholestasis, often complicated with dry gland syndrome due to systemic adenoepithelial cell impairment, or with autoimmune diseases in other organs, the origin of the CA19-9 in the serum is complex. However, the main causes are presumed to be impairment of excretion of bile ingredients due to the above-mentioned lesions in the bile ducts, as well as a decrease in clearance in the liver. The mechanism of increase in serum CA19-9 in patients with diabetes mellitus remains unclarified, but abnormal values exceeding 37 U/ml were shown in 13 of 78 patients (16.7%) treated by the authors. In the majority of these 13 patients in whom CA19-9 was abnormal, the carbohydrate metabolism was under poor control. It may be considered therefore that an imbalance between abnormal metabolism of glucose and lipid existing in the background of patients with diabetes mellitus, may have some association with the increase in CA19-9. According to the report of Del Villano et al., the positive rates of serum GA19-9 in patients with carcinoma of the digestive system were as follows: 63 out of 80 patients (79%) other kinds of cancer of the digestive system.
Further, as mentioned above, there have been some cases of benign diseases where CA19-9 showed an increase, but the majority of the increased levels were below 100 U/ml, whereas in cases of carcinoma of the digestive system, many
show high values, although low values have sometimes been noted. Accordingly, when the GA19-9
value is below 100 U/ml, we should consider an alternative of carcinomatous as well as benign diseases, but when high values over 100 U/ml are indicated, which continue to increase exponential-functionally, it is very important to treat the case with the possibility of cancer of the digestive system in mind.
Whether CA19-9 can be used as a marker for early diagnosis of cancer of the digestive system is an extremely important question in assessing its clinical usefulness as a tumor marker. Since CA19-9 is a glycolipid of product from the secreting epithelium, it is essentially produced easily in adenocarcinoma, and its blood concentration is elevated with increase in the carcinoma. However, in cases of squamous cell carcinoma, as seen in esophageal cancer, the production of GA19-9appears to be very small or none.
Further, there are carcinomas which produce CA19-9 at high levels as well as at low levels, although both presenting the same tissue type of adenocarcinoma at a considerably advanced stage, suggesting that the nature of the CA19-9 production may differ in each case. Clarification of both types in detail histologically is therefore an important future task.
There are generally 2 kinds of tumor markers which can be utilized for the diagnosis of carcinoma of organs over a broad range as well as for the diagnosis of carcinoma of a specific organ. For carcinoma of the digestive system, CEAand ferritin represent the former category, while alpha-fetoprotein and elastase I represent the latter.
To be more specific, CEA can be usefully employed in the diagnosis of biliary cancer, pancreatic cancer, and colorectal cancer; ferritin for primary liver cancer, biliary cancer, and pancreatic cancer; elastase I, for pancreatic cancer, and alpha- In view of the fact that tumor markers of excellent specificity and sensitivity able to detect cancer-bearing organs at an early stage have yet to be established, it is more effective to use available markers in plural numbers rather than singly for the diagnosis of a carcinoma. Although contradictory reports have indicated that in carcinoma of the digestive system, CA19-9 and CEA, and CA19-9 and ferritin are significantly correlated, or are not correlated, the present authors* assessment of the relation between CA19-9 and other tumor markers classified by organ suggested that a correlation between CA19-9
and CEAwas present in stomach cancer, colorectal cancer, pancreatic cancer and biliary cancer, while a correlation between CA19-9 and ferritin was noted in colorectal cancer.
Based on combination assay of CA19-9, CEA and ferritin, in comparison with the positive rates for CA19-9 alone, it was found that the rates were tion assay of CA19-9, CEAand ferritin that while the positive rates on their single use were 42.0% for CA19-9, 47.7% for CEA and 31.8% for ferritin, simultaneous determination with the plural markers was useful for raising the rate of diagnosis, since there was 71.6% with more than 1 positive.
The ultimate value of tumor markers rests on the extent to which an early carcinoma can be diagnosed. Single use of CA19-9 as an auxiliary for early diagnosis is not considered realistic, but combination assay with other tumor markers is expected to enhance the clinical usefulness of these markers.
This study was presented in a part at the 80th Annual Scientific Sesseion of the Japanese Society of Internal Medicine, April, 1984.
